Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis

• Verfasst von: Mackensen, Friederike [VerfasserIn]
• Verfasst von: Jakob, Eva [VerfasserIn]
• Verfasst von: Grewing, Viviane Caroline [VerfasserIn]
• Verfasst von: Lorenz, Hanns-Martin [VerfasserIn]
• Verfasst von: Max, Regina [VerfasserIn]
• Verfasst von: Becker, Matthias D. [VerfasserIn]
• Titel: Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis
• Verf.angabe: Friederike Mackensen, MD, Carsten Heinz, MD, Eva Jakob, MD, Viviane Grewing, MD, Hanns-Martin Lorenz, MD, Arnd Heiligenhaus, MD, Regina Max, MD, and Matthias D. Becker, MD, PhD
• Jahr: 2018
• Jahr des Originals: 2017
• Umfang: 8 S.
• Fussnoten: Published online: 29 Dec 2017 ; Gesehen am 05.08.2019
• Titel Quelle: Enthalten in: Ocular immunology and inflammation
• Ort Quelle: Abingdon : Taylor & Francis Group, 1993
• Jahr Quelle: 2018
• Band/Heft Quelle: 26(2018), 7, Seite 1015-1022
• ISSN Quelle: 1744-5078
• DOI: doi:10.1080/09273948.2017.1411518
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Adalimumab
• Sach-SW: anterior uveitis
• Sach-SW: biological therapy
• Sach-SW: clinical trial
• Sach-SW: uveitis
• K10plus-PPN: 157805088X

Abstract

Purpose: TNF alpha inhibitors have revolutionized the care of vision-threatening uveitis. This study evaluated the efficacy of adalimumab (ADA) for the treatment of refractory noninfectious uveitis.Design: Randomized, prospective, controlled, two-center clinical trialMethods: Patients with active uveitis despite combined oral low-dose prednisolone and immunosuppression were randomized for additional ADA with corticosteroids in a fixed tapering regime, or corticosteroids only. Primary outcome measure at three months was improved best-corrected visual acuity (BCVA; >2 lines). In case of treatment failure, switch to the other arm was possible.Results: Twenty-five patients (10 ADA, 15 controls) were included. BCVA increased with ADA by > 2 lines in 6/10 patients (60%; mean increase of 0.23 logMAR), but in only 2/15 from controls (13%, mean increase of 0.04 logMAR, Fisher´s exact test p = 0.00221).Conclusions: The results show superiority of ADA over controls in severe ocular inflammation including anterior uveitis.